Skip to main content
. Author manuscript; available in PMC: 2018 Aug 30.
Published in final edited form as: Int J Pharm. 2017 Jun 17;529(1-2):32–43. doi: 10.1016/j.ijpharm.2017.06.042

Figure 4.

Figure 4

Transcorneal flux of CIP obtained from various topical NLC formulations tested with different molecular weights of PEG grafted, DSPE phospholipid (PEG-1K (PEG(1K)-CIP-NLCs/2K (PEG(2K)-CIP-NLCs/5K (PEG(5K)-CIP-NLCs) and varied chain lengths of PEG-2000 conjugated phospholipids (DMPE(2K)-CIP-NLCs, DPPE(DPPE(2K)-CIP-NLCs) using side-by-side diffusion cells (PermeGear, Inc) at 34°C (Dose: 3 mL; 0.3% w/v) (n=4). * symbol denotes statistically significant difference of CIP flux from PEG(2K)-CIP-NLCs when compared to DSPE-CIP-NLCs whereas ɸ symbol indicates statistically significant difference of CIP flux from PEG(5K)-CIP-NLCs in comparison to all the formulations (p<0.05).